Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Fresh laboratory data on ...

Carolyn Gusoff has covered some of the most high profile news stories in the New York City area and is best known as a trusted, tenacious, consistent and caring voice of Long Island's concerns. A ...

As vehicles grow more software-dependent, repairing them has become harder than ever. A bill in the US House called the Repair Act would ease those restrictions, but it comes with caveats. Every time ...

If you build engines, tune cars, or even just like mashing your foot on the throttle with conviction, you’ve probably heard the term “wideband O2 sensor” being thrown around at the track, dyno ...

Shares of CRISPR Therapeutics CRSP were up 3.7% yesterday after the company announced encouraging updates from ongoing studies on its next-generation CAR-T therapy candidate, zugocaptagene geleucel or ...

Growing customer use of artificial intelligence (AI) alongside the continued draw of live sports and major gaming releases has resulted in record levels of data consumption across the networks of ...

Virgin Media O2 has released its 2025 Year in Review, revealing record levels of data consumption in the UK, including an 8 per cent rise in broadband usage and an 18 per cent rise in mobile traffic.

93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting 83% overall response and 61% complete ...

ORLANDO, Fla.—The leader of Gilead Sciences' Kite Pharma is sure that anito-cel, the biotech’s next-generation multiple myeloma CAR-T challenger to Carvykti, is ready for prime time—and that the ...

– 96% Overall Response Rate, 74% Stringent Complete Response/Complete Response, and 95% Minimal Residual Disease Negativity Observed at a Median 15.9-months of Follow-up, with Responses Continuing to ...

CAMBRIDGE, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (BEAM) (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced ...